US-Iran Ceasefire Extension Near as Strait of Hormuz Shipping Deal Advances 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Netanyahu Orders Expansion of Israeli Control in Gaza to 70% 
Baltic Drone Incidents Raise NATO Security Concerns 
DOJ Opens Criminal Investigation Into E. Jean Carroll Over Alleged Perjury 
Judge Dismisses Trump Administration Lawsuit Against Boston Sanctuary City Policy 
U.S. Reinstates Sanctions on U.N. Expert Francesca Albanese Amid Legal Battle 
Trump Administration Threatens Newark Airport International Travel Shutdown Over Immigration Dispute 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
US Designates Brazil’s PCC and Comando Vermelho as Global Terrorist Entities Ahead of FTO Listing 
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
U.S. Lawmakers Back Ukraine’s Request for More Patriot Missiles Amid Rising Russian Attacks 
Flavio Bolsonaro Meets Trump, JD Vance, and Marco Rubio Amid Brazil Political Crisis 
U.S.-China Taiwan Conflict Could Trigger Nuclear Escalation, IISS Warns 
UN Blacklists Israel and Russia Over Conflict-Related Sexual Violence Claims 
Trump Signs Executive Order to Expand Access to Federal Lands in the U.S. 
Trump administration officials have reportedly explored ways to reduce the operational role of U.S. Food and Drug Administration (FDA) Commissioner Marty Makary, according to a Wall Street Journal report citing individuals familiar with internal discussions. The conversations, which allegedly involved Health Secretary Robert F. Kennedy Jr., focused on concerns over internal disputes among the commissioner’s top deputies and the overall management of the agency.
Sources claim Kennedy considered bringing in another senior leader to take charge of the FDA’s day-to-day responsibilities while keeping Makary in a more symbolic leadership position. The idea was intended to stabilize internal dynamics and strengthen the agency’s decision-making structure. However, officials have chosen to hold off on restructuring for now, giving Makary additional time to address leadership issues and improve cohesion within the FDA.
A White House spokesperson affirmed that the administration remains confident in both the Department of Health and Human Services and the FDA. The spokesperson emphasized that the agency, under Makary’s direction, continues to advance initiatives designed to support President Donald Trump’s commitment to “Make America Healthy Again,” highlighting efforts focused on improving public health and regulatory efficiency.
In a key leadership update, the FDA recently appointed renowned oncology expert Richard Pazdur to oversee the division responsible for regulating most prescription and over-the-counter medications. Pazdur’s appointment follows the resignation of George Tidmarsh earlier this month after concerns surfaced regarding his personal conduct, prompting the agency to accelerate leadership changes in this critical department.
As discussions about the FDA’s internal structure evolve, the administration appears intent on maintaining stability while pushing forward with major health and regulatory initiatives. Despite earlier considerations of reassigning responsibilities, officials now seem focused on giving Makary the opportunity to strengthen his leadership and guide the agency through ongoing reforms.
